# A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline

> **NCT07732387** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Yanping Kong** · enrollment: 30 (estimated)

## Conditions studied

- Erectile Dysfunctions
- Healthy Volunteer

## Interventions

- **DRUG:** Viaca
- **DRUG:** Sildenafil 50 mg
- **DRUG:** Cabergoline 0.5 MG

## Key facts

- **NCT ID:** NCT07732387
- **Lead sponsor:** Yanping Kong
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2026-09-19
- **Final completion:** 2026-09-19
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07732387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07732387, "A Study to Assess the Safety, Tolerability and Pharmacokinetics of Viaca (Sildenafil + Cabergoline) Compared With Sildenafil and Cabergoline". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07732387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*